How many drug targets are there?
The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
For the past decade, the number of molecular targets for approved drugs has been debated. Here, we reconcile apparently contradictory previous reports into a comprehensive survey, and propose a consensus number of current drug targets for all classes of approved therapeutic drugs. One striking feature is the relatively constant historical rate of target innovation (the rate at which drugs against new targets are launched); however, the rate of developing drugs against new families is significantly lower. The recent approval of drugs that target protein kinases highlights two additional trends: an emerging realization of the importance of polypharmacology, and also the power of a gene-family-led approach in generating novel and important therapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, G-protein-coupled receptors (GPCRs) are influenced by trafficking progress and then internalized in the cell membrane and recycled or degraded.”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [127]
In the citing paper
“Covalent molecules may not be able to effectively target GPCRs during this turnover process [127].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [127]
Citations
Cites
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
The Pfam Protein Families Database
Bateman, A. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.276 · Cited by 14,000
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Murzin, A. G., Brenner, S. E., Hubbard, T., & Chothia, C. (1995) · Journal of Molecular Biology · doi:10.1016/s0022-2836(05)80134-2 · Cited by 7,012 · cited 1×
“Patterns in drug targets In order to identify the familial relationships between all drug targets, we analysed the presence of domains, using the SCO”
MethodDrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305 · cited 1×
“drugs acted primarily through only 120 underlying molecular target”
BackgroundSelf-citationThe Pfam protein families database
Bateman, A. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh121 · Cited by 3,127
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967 · cited 1×
“Imatinib, originally developed as a highly selective inhibitor of c-AB”
BackgroundA small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892 · cited 1×
“(and which target association led to its first approval for chronic myeloid leukaemia), has subsequently been discovered to be have significant activity against several other clinically relevant kinases, such as c-KI”
Background
Research works printed but not linked: 1
- Christensen, C. M. The Innovator's Dilemma: When New Technologies Cause Great Firms to Fail (Harvard Business School Press, Cambridge, 1997).
Cited by
Items 501–600 of 1,024
RNA –ligand molecular docking: Advances and challenges
Zhou, Y., Jiang, Y., & Chen, S. (2021) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1571 · Cited by 110
Single-domain antibodies for biomedical applications
Krah, S., Schröter, C., Zielonka, S., Empting, M., Valldorf, B., & Kolmar, H. (2015) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2015.1102934 · Cited by 99
Roth, B. L., & Kroeze, W. K. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.654764 · Cited by 88
“G-protein-coupled receptors (GPCRs;(2) 7-transmembrane domain receptors) historically have represented both the most abundant and the most popular gene superfamily for therapeutic drug discovery and development, with perhaps 30 – 40% of approved drugs targeting the non-olfactory GPCRs (1, 2).”
BackgroundChen, D., Errey, J. C., Heitman, L. H., Marshall, F. H., IJzerman, A. P., & Siegal, G. (2012) · ACS Chemical Biology · doi:10.1021/cb300436c · Cited by 88
“Thus, it is not surprising that about 30% of all prescribed drugs on the market act on this class of receptors.(3) In the last ten years, GPCR drug discovery has relied on cell-based assays combined with high-throughput screening (HTS) of large compound libraries(4) for lead discovery as well as optimization.”
BackgroundAshtawy, H. M., & Mahapatra, N. R. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00309 · Cited by 94
Defining a conformational ensemble that directs activation of PPARγ
Chrisman, I. M., Nemetchek, M. D., de Vera, I. M. S., Shang, J., Heidari, Z., Long, Y., Reyes-Caballero, H., Galindo‐Murillo, R., Cheatham, T. E., Blayo, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04176-x · Cited by 95
“(2) Some spectra were run twice utilizing protein from the same batch as utilized for the first spectra or from an entirely different protein preparation.”
MethodChemical, Target, and Bioactive Properties of Allosteric Modulation
van Westen, G. J. P., Gaulton, A., & Overington, J. P. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003559 · Cited by 85
“300 family members in the human genome), and linkage to many important diseases [4].”
BackgroundSelf-citationCarnitine in metabolic disease: Potential for pharmacological intervention
Arduini, A., Bonomini, M., Savica, V., Amato, A., & Zammit, V. A. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.08.008 · Cited by 95
Liu, T., Naderi, M., Alvin, C., Mukhopadhyay, S., & Bryliński, M. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00596 · Cited by 89
Safety screening in early drug discovery: An optimized assay panel
Bendels, S., Bissantz, C., Fasching, B., Gerebtzoff, G., Guba, W., Kansy, M., Migeon, J., Mohr, S., Peters, J., Tillier, F., et al. (2019) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2019.106609 · Cited by 90
Stimuli-activatable PROTACs for precise protein degradation and cancer therapy
Gao, J., Yang, L., Lei, S., Zhou, F., Nie, H., Peng, B., Xu, T., Chen, X., Yang, X., Sheng, C., et al. (2023) · Science Bulletin · doi:10.1016/j.scib.2023.04.028 · Cited by 87
Strategies for the identification of allosteric modulators of G-protein-coupled receptors
Burford, N. T., Watson, J., Bertekap, R. L., & Alt, A. J. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.12.012 · Cited by 99
Leyris, J.-P., Roux, T., Trinquet, E., Verdié, P., Fehrentz, J., Oueslati, N., Douzon, S., Bourrier, E., Lamarque, L., Gagne, D., et al. (2010) · Analytical Biochemistry · doi:10.1016/j.ab.2010.09.030 · Cited by 94
Fiedler, S., Broecker, J., & Keller, S. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0259-0 · Cited by 96
“contrast to the biological and pharmacological significance of membrane proteins, as they account for roughly 30% of open reading frames in the human genome [2] and represent more than 50% of drug targets in the human body [3].”
Transcription Factor Beacons for the Quantitative Detection of DNA Binding Activity
Vallée‐Bélisle, A., Bonham, A. J., Reich, N. O., Ricci, F., & Plaxco, K. W. (2011) · Journal of the American Chemical Society · doi:10.1021/ja204775k · Cited by 88
Berthing, T., Bonde, S., Sørensen, C. B., Utko, P., Nygård, J., & Martinez, K. L. (2011) · Small · doi:10.1002/smll.201001642 · Cited by 94
Bioinformatics and variability in drug response: a protein structural perspective
Lahti, J. L., Tang, G. W., Capriotti, E., Liu, T., & Altman, R. B. (2012) · Journal of The Royal Society Interface · doi:10.1098/rsif.2011.0843 · Cited by 89
Global vision of druggability issues: applications and perspectives
Hussein, H. A., Geneix, C., Petitjean, M., Borrel, A., Flatters, D., & Camproux, A. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.11.021 · Cited by 102
Breaking the barriers in membrane protein crystallography
Kang, H. J., Lee, C., & Drew, D. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.12.018 · Cited by 102
Keener, J. E., Zambrano, D. E., Zhang, G., Zak, C. K., Reid, D. J., Deodhar, B. S., Pemberton, J. E., Prell, J. S., & Marty, M. T. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b11529 · Cited by 92
Killing by Degradation: Regulation of Apoptosis by the Ubiquitin-Proteasome-System
Abbas, R., & Larisch, S. (2021) · Cells · doi:10.3390/cells10123465 · Cited by 95
Expanding medicinal chemistry space
Barker, A. J., Kettle, J. G., Nowak, T., & Pease, J. E. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.10.008 · Cited by 104
Glucose-Neopentyl Glycol (GNG) amphiphiles for membrane protein study
Chae, P. S., Rana, R. R., Gotfryd, K., Rasmussen, S. G. F., Kruse, A. C., Cho, K. H., Capaldi, S., Carlsson, E., Kobilka, B. K., Loland, C. J., et al. (2012) · Chemical Communications · doi:10.1039/c2cc36844g · Cited by 86
Fontaine, F., Overman, J., & François, M. (2015) · Cell Regeneration · doi:10.1186/s13619-015-0015-x · Cited by 86
“More than 50% of these drugs target three types of proteins only, class I G protein-coupled receptors (GPCR; 27%), nuclear receptors (13%), and ion channels (13%) [55,56].”
BackgroundIntracellular Transfer of Na+ in an Active-State G-Protein-Coupled Receptor
Vickery, O. N., Carvalheda, C. A., Zaidi, S. A., Pisliakov, A. V., Katritch, V., & Zachariae, U. (2017) · Structure · doi:10.1016/j.str.2017.11.013 · Cited by 90
Maïga, A., Lemieux, S., Pabst, C., Lavallée, V.-P., Bouvier, M., Sauvageau, G., & Hébert, J. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.36 · Cited by 89
“10 Although GPCRs are targets for approximately 30% of all marketed drugs, 11 only a very limited number of agonists or antagonists acting through these receptors are currently used for cancer therapy.”
Recent progress on nuclear receptor RORγ modulators
Cyr, P., Bronner, S. M., & Crawford, J. J. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.08.012 · Cited by 90
Husain, B., Ramani, S. R., Chiang, E. Y., Lehoux, I. E., Paduchuri, S., Arena, T. A., Patel, A., Wilson, B., Chan, P., Franke, Y., et al. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.tir119.001433 · Cited by 92
Expression of eukaryotic membrane proteins in eukaryotic and prokaryotic hosts
Kesidis, A., Depping, P., Lodé, A., Vaitsopoulou, A., Bill, R. M., Goddard, A. D., & Rothnie, A. J. (2020) · Methods · doi:10.1016/j.ymeth.2020.06.006 · Cited by 101
“Over the last few years, there has been a high demand for obtaining in-depth information for membrane proteins due to their association with human pathophysiology, which makes them targets for drug discovery [1-3].”
BackgroundKooistra, A. J., Kuhne, S., de Esch, I. J. P., Leurs, R., & de Graaf, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12248 · Cited by 95
“The family of GPCRs is a particularly interesting system for chemogenomic analyses for several reasons: (i) GPCRs are targeted by ∼30% of the currently marketed drugs (Overington et al., 2006); (ii) large experimental GPCR ligand binding data sets are available (Knox et al.”
BackgroundComputational analysis of ligand relationships within target families
Bajorath, J. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.01.044 · Cited by 92
Biological responses towards cationic peptides and drug carriers
Verdurmen, W. P. R., & Brock, R. E. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.11.005 · Cited by 88
Computational toxicology: an overview of the sources of data and of modelling methods
Nigsch, F., Macaluso, M., Mitchell, J. B. O., & Zmuidinavicius, D. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250802660467 · Cited by 95
“So far, structure-based techniques have been rare in computational toxicology [93,96] .”
BackgroundMethodGudleski-O'Regan, N., Greco, T. M., Cristea, I. M., & Shenk, T. (2012) · Cell Host & Microbe · doi:10.1016/j.chom.2012.05.012 · Cited by 84
“Cell surface proteins comprise more than a third of the human proteome (Josic and Clifton, 2007), they are often altered on diseased cells and they serve as targets for more than two-thirds of existing drugs (Overington et al., 2006).”
BackgroundMedium-Chain Lipid Conjugation Facilitates Cell-Permeability and Bioactivity
Morstein, J., Capecchi, A., Hinnah, K., Park, B., Petit-Jacques, J., Lehn, R. C. V., Reymond, J., & Trauner, D. H. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c07833 · Cited by 90
HTS and hit finding in academia – from chemical genomics to drug discovery
Frearson, J. A., & Collie, I. T. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.09.004 · Cited by 91
“It is currently estimated that all of the FDA-approved drugs collectively address just 324 targets (of which 266 are human) [39].”
BackgroundKomatsu, H., Maruyama, M., Shuuhei, Y., Shinohara, T., Sakuma, K., Imaichi, S., Chikatsu, T., Kuniyeda, K., Siu, F. K., Peng, L. S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090134 · Cited by 90
“Hence, non-odorant GPCRs comprise one of the most important therapeutic target repertoires and account for 28% of all current drug targets[1].”
BackgroundMay, L. T., Bridge, L., Stoddart, L. A., Briddon, S. J., & Hill, S. J. (2011) · The FASEB Journal · doi:10.1096/fj.11-186296 · Cited by 98
“Global analysis estimated the pEC50 for XAC, NECA, and adenosine at the A3-AR as 6.0 0.1, 5.9 0.1 and 5.2 0.1, respectively (n 3–11 separate experiments, where each replicate represents the average of 10 cells).”
InfluentialFunctional profiles of orphan membrane transporters in the life cycle of the malaria parasite
Kenthirapalan, S., Waters, A. P., Matuschewski, K., & Kooij, T. W. A. (2016) · Nature Communications · doi:10.1038/ncomms10519 · Cited by 91
“Broadly, these genetically arrested parasites fall into two distinct classes: (1) early arrested liver stages that fail to grow in cultured hepatoma cells and show a reduced liver load in vivo, and (2) late arrested parasites that initially grow normally but have a defect in liverstage merozoite formation, correlating…”
BackgroundMolecular dynamics analysis to evaluate docking pose prediction
Sakano, T., Mahamood, M. I., Yamashita, T., & Fujitani, H. (2016) · Biophysics and Physicobiology · doi:10.2142/biophysico.13.0_181 · Cited by 91
Doyle, M., Gasser, R. B., Woodcroft, B. J., Hall, R. S., & Ralph, S. A. (2010) · BMC Genomics · doi:10.1186/1471-2164-11-222 · Cited by 89
“We focused on enzymes, ion channels and G-proteincoupled receptors (GPCRs) because the vast majority of all drugs target these classes [49,66] and chemicals already exist to interrogate such targets.”
BackgroundExploring Polypharmacology Using a ROCS-Based Target Fishing Approach
AbdulHameed, M. D. M., Chaudhury, S., Singh, N. P., Sun, H., Wallqvist, A., & Tawa, G. J. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci2003544 · Cited by 85
Impedance-based cellular assay technologies: recent advances, future promise
McGuinness, R. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2007.08.004 · Cited by 83
Selecting, Acquiring, and Using Small Molecule Libraries for High‐Throughput Screening
Dandapani, S., Rossé, G., Southall, N. T., Salvino, J. M., & Thomas, C. J. (2012) · Current Protocols in Chemical Biology · doi:10.1002/9780470559277.ch110252 · Cited by 95
“Although the number of drug targets is debatable (Overington et al., 2006), it is likely that many traditional compound libraries are inadequate for targeting macromolecule interactions such as protein-protein interactions and nucleic acid-protein interactions.”
BackgroundMass Spectrometry Methods for Measuring Protein Stability
Vallejo, D. D., Ramírez, C. R., Parson, K. F., Han, Y., Gadkari, V. V., & Ruotolo, B. T. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00857 · Cited by 95
Fragment screening by SPR and advanced application to GPCRs
Shepherd, C., Hopkins, A. L., & Navratilova, I. H. (2014) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2014.09.008 · Cited by 95
Self-citationDistinct Biological Network Properties between the Targets of Natural Products and Disease Genes
Dančík, V., Seiler, K. P., Young, D. W., Schreiber, S. L., & Clemons, P. A. (2010) · Journal of the American Chemical Society · doi:10.1021/ja102798t · Cited by 88
Molecular Basis of Ligand Dissociation from the Adenosine A2A Receptor
Guo, D. M., Pan, A. C., Dror, R. O., Mocking, T. A. M., Liu, R., Heitman, L. H., Shaw, D. E., & IJzerman, A. P. (2016) · Molecular Pharmacology · doi:10.1124/mol.115.102657 · Cited by 84
“We started from a crystal structure of a GPCR, being the most prevalent drug targets (Overington et al., 2006), with its cocrystallized ligand.”
BackgroundMembrane proteins: always an insoluble problem?
Rawlings, A. E. (2016) · Biochemical Society Transactions · doi:10.1042/bst20160025 · Cited by 82
canSAR: an integrated cancer public translational research and drug discovery resource
Halling-Brown, M. D., Bulusu, K. C., Patel, M., Tym, J. E., & Al-Lazikani, B. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr881 · Cited by 84
“The approved drugs from the FDA are captured (regardless of therapeutic indication) and their efficacy targets were expert-curated from published literature (38).”
BackgroundSelf-citationBojadzic, D., & Buchwald, P. (2018) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026618666180531092503 · Cited by 82
“Existing small-molecule drugs average a value of around 20 nM, and it is generally desirable to have sub-micromolar (<1 μM) potency for lead compounds [88].”
BackgroundHighlighting membrane protein structure and function: A celebration of the Protein Data Bank
Li, F., Egea, P. F., Vecchio, A. J., Asial, I., Gupta, M., Paulino, J., Bajaj, R., Dickinson, M. S., Ferguson-Miller, S., Monk, B. C., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100557 · Cited by 81
Drug delivery challenges and formulation aspects of proteolysis targeting chimera (PROTACs)
Saraswat, A. L., Vartak, R., Hegazy, R. R., Patel, A., & Patel, K. R. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103387 · Cited by 92
GOMoDo: A GPCRs Online Modeling and Docking Webserver
Sandal, M., Tran, D. P., Cona, M., Zung, H., Carloni, P., Musiani, F., & Giorgetti, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074092 · Cited by 84
“GPCRs are a vast superfamily of eukaryotic transmembrane receptors which act as ubiquitously expressed key regulatory elements and constitute more than 30% of current drug targets [1].”
BackgroundAshtawy, H. M., & Mahapatra, N. R. (2015) · IEEE/ACM Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2014.2351824 · Cited by 80
Diversity of Potassium Channel Ligands: Focus on Scorpion Toxins
Kuzmenkov, A. I., Grishin, E. V., & Vassilevski, A. A. (2015) · Biochemistry (Moscow) · doi:10.1134/s0006297915130118 · Cited by 89
“At present, ~13% of all medicinal compounds sold on the pharmaceutical market affect ion channels [242], which puts these mem brane proteins in second place of the most widely used pharmacological targets after G protein coupled receptors [243].”
BackgroundAndrade, E., Bento, A. F., Cavalli, J., de Oliveira, S. K. F., Freitas, C. S., Marcon, R., Schwanke, R. C., Siqueira, J. M., & Calixto, J. Β. (2016) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20165644 · Cited by 99
“Enzymes such as kinases, proteases, phosphatases, oxidoreductases, phosphodiesterases, and transferases, among others, comprise the majority of biochemical targets in today’s new molecules’ discovery (37,38).”
BackgroundYan, N. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.07.009 · Cited by 101
New Mass-Spectrometry-Compatible Degradable Surfactant for Tissue Proteomics
Chang, Y.-H., Gregorich, Z. R., Chen, A. J., Hwang, L., Guner, H., Yu, D., Zhang, J., & Ge, Y. (2015) · Journal of Proteome Research · doi:10.1021/pr5012679 · Cited by 80
Archbold, J. K., Flanagan, J. U., Watkins, H. A., Gingell, J. J., & Hay, D. L. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.05.007 · Cited by 80
Modulating transcription factor activity: Interfering with protein-protein interaction networks
François, M., Donovan, P., & Fontaine, F. R. (2018) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2018.07.019 · Cited by 95
Multiplex single-molecule interaction profiling of DNA-barcoded proteins
Gu, L., Li, C., Aach, J., Hill, D. E., Vidal, M., & Church, G. M. (2014) · Nature · doi:10.1038/nature13761 · Cited by 85
Miki, T., Fujishima, S., Komatsu, K., Kuwata, K., Kiyonaka, S., & Hamachi, I. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.07.013 · Cited by 82
Hypoxia‐inducible factor‐1 as a therapeutic target in cancer
Tang, C., & Yu, J. Q. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12038 · Cited by 84
The Role of Anethum graveolens L. (Dill) in the Management of Diabetes
Goodarzi, M. T., Khodadadi, I., Tavilani, H., & Abbasi Oshaghi, E. (2016) · Journal of Tropical Medicine · doi:10.1155/2016/1098916 · Cited by 68
Gogliotti, R. G., Senter, R. K., Fisher, N. M., Adams, J., Zamorano, R., Walker, A. G., Blobaum, A. L., Engers, D. W., Hopkins, C. R., Daniels, J. S., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aai7459 · Cited by 85
“Food and Drug Administration–approved drugs (49).”
Cell-surface proteomics for the identification of novel therapeutic targets in cancer
Kuhlmann, L., Cummins, E., Samudio, I., & Kislinger, T. (2018) · Expert Review of Proteomics · doi:10.1080/14789450.2018.1429924 · Cited by 81
“approved drugs target the surfaceome [23,29,30].”
Drug‐Like Properties in Macrocycles above MW 1000: Backbone Rigidity versus Side‐Chain Lipophilicity
Furukawa, A., Schwochert, J., Pye, C. R., Asano, D., Edmondson, Q. D., Turmon, A. C., Klein, V. G., Ono, S., Okada, O., & Lokey, R. S. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202004550 · Cited by 79
Repurposing of Antimicrobial Agents for Cancer Therapy: What Do We Know?
Pfab, C., Schnobrich, L., Eldnasoury, S., Gessner, A., & El‐Najjar, N. (2021) · Cancers · doi:10.3390/cancers13133193 · Cited by 87
“Traditionally, drug’s off-targets are often considered responsible for toxic side effects; yet, although this is truthful in many cases, inadvertent target inhibition per se may elicit unexpected beneficial effects in a different disease context [5,12].”
BackgroundChakraborty, C., Bhattacharya, M., Lee, S., Wen, Z., & Lo, Y.-H. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102295 · Cited by 100
“96,97 However, protein plays a signi fi cant role in cell-cell transduction and cell signaling.”
BackgroundWhitby, R. J., Stec, J., Blind, R. D., Dixon, S., Leesnitzer, L. M., Orband‐Miller, L. A., Williams, S. P., Willson, T. M., Xu, R. X., Zuercher, W. J., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm1014296 · Cited by 92
Chang, C., & McDonnell, D. P. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3221 · Cited by 84
Zhao, X., Jones, A. D., Olson, K. R., Peng, K., Wehrman, T. S., Park, A., Mallari, R., Nebalasca, D., Young, S. W., & Xiao, S.-H. (2008) · SLAS DISCOVERY · doi:10.1177/1087057108321531 · Cited by 83
Allosteric modulators targeting CNS muscarinic receptors
Böck, A., Schrage, R., & Mohr, K. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.09.024 · Cited by 91
Understanding Membrane Protein Drug Targets in Computational Perspective
Gong, J., Chen, Y., Pu, F., Sun, P., He, F., Zhang, L., Li, Y., Ma, Z., & Wang, H. (2018) · Current Drug Targets · doi:10.2174/1389450120666181204164721 · Cited by 87
Kant, S., Deepika, & Roy, S. (2025) · Discover Pharmaceutical Sciences · doi:10.1007/s44395-025-00007-3 · Cited by 104
“Similarly, AI can analyze proteomic data, such as protein structures and interactions, to identify proteins involved in disease pathways and assess their druggability [21, 22].”
Eleftheriou, P. T., Geronikaki, A. A., Hadjipavlou‐Litina, D., Vicini, P., Filz, O., Filimonov, D. A., Poroikov, V., Chaudhaery, S. S., Roy, K. K., & Saxena, A. K. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.10.029 · Cited by 88
Weitz, E. A., Chang, J. Y., Rosenfield, A. H., Morrow, E. A., & Pierre, V. C. (2013) · Chemical Science · doi:10.1039/c3sc51583d · Cited by 87
Bivalent Ligands of CXCR4 with Rigid Linkers for Elucidation of the Dimerization State in Cells
Tanaka, T., Nomura, W., Narumi, T., Masuda, A., & Tamamura, H. (2010) · Journal of the American Chemical Society · doi:10.1021/ja107447w · Cited by 78
Rizk, M. A., El‒Sayed, S. A. E., Terkawi, M. A., Youssef, M. A., Said, E. S. E. S. E., El‐Sayed, G., El‐Khodery, S., El-Ashker, M. R., Elsify, A. M., Omar, M. A., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125276 · Cited by 78
Grossfield, A. M. (2011) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2011.03.010 · Cited by 85
Direct Modulation of Small GTPase Activity and Function
Cromm, P. M., Spiegel, J., Grossmann, T. N., & Waldmann, H. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201504357 · Cited by 76
Extracellular cues influencing oligodendrocyte differentiation and (re)myelination
Wheeler, N. A., & Fuss, B. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.03.019 · Cited by 92
“…ligands: G protein (heterotrimeric guanine nucleotide–binding protein)–coupled receptors (GPCRs) are the largest class of cell surface receptors, and they have been proven as attractive drug targets (Jacobson, 2015; Kumari et al., 2015; Overington et al., 2006; Rask-Andersen et al., 2011).”
Daughton, C. G. (2010) · ACS symposium series · doi:10.1021/bk-2010-1048.ch002 · Cited by 95
Emerging Approaches to GPCR Ligand Screening for Drug Discovery
Kumari, P., Ghosh, E., & Shukla, A. K. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.09.002 · Cited by 77
Recent Progress in Repositioning Alzheimer'S Disease Drugs Based on a Multitarget Strategy
Santos, M. A., Chand, K., & Chaves, S. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0103 · Cited by 78
Optical and Electronic Ion Channel Monitoring from Native Human Membranes
Pappa, A., Liu, H., Traberg, W. C., Thiburce, Q., Savva, A., Pavia, A., Salleo, A., Daniel, S., & Owens, R. M. (2020) · ACS Nano · doi:10.1021/acsnano.0c01330 · Cited by 77
Inhibition of Heterotrimeric G Protein Signaling by a Small Molecule Acting on Gα Subunit
Ayoub, M. A., Damian, M., Gespach, C. P., Ferrandis, E., Lavergne, O., Wever, O. D., Banères, J., Pin, J., & Prevost, G. P. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.042333 · Cited by 77
Fragment-guided design of subnanomolar β-lactamase inhibitors active in vivo
Eidam, O., Romagnoli, C., Dalmasso, G., Barelier, S., Caselli, E., Bonnet, R., Shoichet, B. K., & Prati, F. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208337109 · Cited by 76
Maturing of the nuclear receptor family
Lazar, M. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92949 · Cited by 84
“org Volume 127 Number 4 April 2017 imately 13% of all drugs approved by the United States Food and Drug Administration target NRs (31).”
A biased ligand for OXE-R uncouples Gα and Gβγ signaling within a heterotrimer
Blättermann, S., Peters, L., Ottersbach, P. A., Böck, A., Kónya, V., Weaver, C. D., González, Á., Schröder, R. J., Tyagi, R., Luschnig, P., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.962 · Cited by 78
Lipid Membrane Mimetics in Functional and Structural Studies of Integral Membrane Proteins
Majeed, S., Ahmad, A., Sehar, U., & Georgieva, E. R. (2021) · Membranes · doi:10.3390/membranes11090685 · Cited by 90
“Notably, it is remarkable that almost 40% of all FDA-approved drugs exploit IMPs as their molecular targets [8,9].”
BackgroundmGlu5negative allosteric modulators: a patent review (2013 - 2016)
Emmitte, K. A. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1280466 · Cited by 79
The acid–base profile of a contemporary set of drugs: implications for drug discovery
Manallack, D. T. (2009) · SAR and QSAR in environmental research · doi:10.1080/10629360903438313 · Cited by 76
“Interestingly, the CNS class of compounds was shown to be rich in amines as they often target G-protein coupled receptor proteins 37 where the key recognition element in the binding site is an aspartic acid residue 38 .”
BackgroundSolution NMR study of integral membrane proteins
Kang, C., & Li, Q. (2011) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2011.05.025 · Cited by 83
Liu, C., Bonaventure, P., Lee, G., Nepomuceno, D. H., Kuei, C., Wu, J., Li, Q. S., Joseph, V. T., Sutton, S. W., Eckert, W. A., et al. (2015) · Molecular Pharmacology · doi:10.1124/mol.115.100412 · Cited by 84
“Given the importance of GPCRs in many aspects of physiology, they are among the most pursued targets for drug development (Heng et al., 2013; Lundstrom and Chiu, 2005; Overington et al., 2006).”
BackgroundZhao, Y., Xu, L., Ding, S. Z., Lin, N., Ji, Q., Gao, L., Su, Y., He, B., & Pu, J. (2016) · Journal of Pineal Research · doi:10.1111/jpi.12378 · Cited by 78
Meng, F., You, Z., Chen, X., Zhou, Y. Z., & An, J. (2017) · Molecules · doi:10.3390/molecules22071119 · Cited by 79
As the world grows: contraception in the 21st century
Aitken, R. J., Baker, M. A., Doncel, G. F., Matzuk, M. M., Mauck, C. K., & HARPER, M. J. K. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33873 · Cited by 78
“Bioinformatic analyses of these data suggest that approximately 2% of the sperm proteome is amenable for drug-target validation, with several leading candidates currently in the pipeline for further development, such as the odor-ant receptors (ORs) and sperm thioredoxins mentioned below (70).”
BackgroundDendritic ion channelopathy in acquired epilepsy
Poolos, N. P., & Johnston, D. (2012) · Epilepsia · doi:10.1111/epi.12033 · Cited by 75
“…molecular targets for pharmaceuticals (approximately 10–15% of all U.S. Food and Drug Administration (FDA)–approved drugs act on ion channels, Overington et al., 2006), and changes in their biophysical properties in the epileptic state provide both opportunities and challenges for the…”
Metadata
- Authors
- Overington, J. P., Al-Lazikani, B., & Hopkins, A. L.
- Affiliations
- Pfizer (United Kingdom) (GB)
- Corresponding author
- Overington, John P.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-12
- Volume
- 5
- Issue
- 12
- Pages
- 993-996
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1968682237
- Cited by
- 3,505
- References
- 29
- Citations by year
- 2026: 82 · 2025: 126 · 2024: 117 · 2023: 127 · 2022: 173 · 2021: 168 · 2020: 190 · 2019: 190 · 2018: 198 · 2017: 215 · 2016: 276 · 2015: 268 · 2014: 245 · 2013: 280 · 2012: 247
- FWCI
- 7.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- therapeutic target, molecular targets, protein kinases, polypharmacology, approved drugs
- MeSH terms
- Humans, Technology, Pharmaceutical, Drug Design, Drugs, Investigational, Genome, Human, Drug Delivery Systems, Drug Approval
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.